FDA Lifts Clinical Hold on Rein Therapeutics' LTI-03 Trial

Strategic Insights -

Rein Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This decision follows a review of Rein's submission, which addressed all of the agency's concerns. The FDA's confirmation allows the study to proceed, and Rein expects to resume patient recruitment in late 2025 or early 2026 across approximately 20 U.S. clinical sites.

Key Takeaways:

  • The FDA has lifted the full clinical hold on Rein Therapeutics' Phase 2 "RENEW" trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF), allowing the study to proceed.
  • Rein expects to resume patient recruitment in late 2025 or early 2026 across approximately 20 U.S. clinical sites.
  • The trial is designed to evaluate the safety, tolerability, and efficacy of LTI-03 in up to 120 patients with IPF, with key secondary endpoints including changes in lung function (FVC) and imaging-based measures of fibrosis progression.
  • Initial top-line data is expected in Q3 2026.
  • Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing.
  • LTI-03 is a first-in-class, inhaled peptide therapy derived from Caveolin-1 biology, a key regulator of fibrotic signaling.
  • The global market for fibrosis treatments is projected to exceed $11 billion by 2031.

Statistics:

  • 20 U.S. clinical sites will be involved in the resumed patient recruitment.
  • The trial will include up to 120 patients with IPF.
  • Initial top-line data is expected in Q3 2026.
  • The global market for fibrosis treatments is projected to exceed $11 billion by 2031.

Sources:

  • Globe Newswire, "Rein Therapeutics Announces FDA Lifts Full Clinical Hold on Phase 2 RENEW Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)" (November 3, 2025)
  • Rein Therapeutics, "Rein Therapeutics Announces FDA Lifts Full Clinical Hold on Phase 2 RENEW Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)" (November 3, 2025)